New studies on GLP-1 The discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is a significant concern for individuals managing conditions like obesity and type 2 diabetes, as it often leads to a reversal of treatment benefits, most notably weight regain. Studies indicate that a substantial percentage of patients, often exceeding 50%, stop taking these medications within the first year of treatment. This trend raises critical questions about the long-term efficacy and sustainability of GLP-1 RA therapy, prompting a deeper examination of the clinical, policy, and equity implications surrounding their cessationDiscontinuation of Glucagon-Like Peptide-1 Receptor ....
Real-world data consistently demonstrate high rates of discontinuation for GLP-1 receptor agonists作者：T Weiss·2020·被引用次数：109—Conclusion: Over half of T2DM patients initiatingGLP-1RA were non-adherent and the majority (70.1%)discontinuedtherapy by 24 months. Reasons .... Within a year of initiation, estimates vary, but many studies report that between 50% and 75% of patients cease treatment. Some research indicates even higher one-year discontinuation rates, reaching up to 74%. These figures are particularly pronounced in individuals with overweight and obesity who do not have type 2 diabetes. The reasons behind these high dropout rates can be multifaceted, encompassing factors such as cost, side effects, perceived lack of continued efficacy, or changes in treatment guidelines and accessibility.作者：PJ Rodriguez·2025·被引用次数：147—Discontinuation is the first date a patient is 60 days or morewithout any GLP-1 RA medication on hand. Reinitiation is the first fill of any ...
A primary concern following the discontinuation of GLP-1 RAs is the predictable and often rapid weight regain. Research suggests that individuals are likely to regain a significant portion of the lost weight after stopping therapy作者：PJ Rodriguez·2025·被引用次数：147—Discontinuation is the first date a patient is 60 days or morewithout any GLP-1 RA medication on hand. Reinitiation is the first fill of any .... This phenomenon, sometimes referred to as a "rebound," can occur regardless of lifestyle interventions. Beyond weight, the cessation of GLP-1 RAs can also lead to a metabolic rebound, affecting systolic blood pressure and glycemic control in patients with type 2 diabetes. The loss of these benefits underscores the importance of sustained treatment for achieving and maintaining health outcomes associated with these medicationsTrajectory of weight regain after cessation of GLP-1 ....
Understanding the drivers of discontinuation is crucial for improving patient outcomes. While specific reasons are not always explicitly detailed in every study, common factors contributing to patients stopping treatment likely include the financial burden of these medications, the emergence of adverse events that outweigh perceived benefits, or a misunderstanding of the long-term nature of treatment required for sustained resultsReal-world weight change, adherence, and discontinuation .... Adherence rates also play a significant role; studies have shown that a considerable portion of patients initiating GLP-1 RAs may be non-adherent, which can precede full discontinuation作者：I Abdullah bin Ahmed·2024·被引用次数：27—The main concern with the use of GLP-1RA treatment wasweight gain after withdrawal or discontinuation. We could identify three different ways that could lead .... The duration of treatment and dosing frequency have also been identified as factors that can influence discontinuation patterns.
The high discontinuation rates of GLP-1 receptor agonists also carry significant policy and equity implications.Discontinuing glucagon-like peptide-1 receptor agonists ... As these medications become more widely prescribed for obesity and related conditions, ensuring equitable access and long-term adherence becomes paramount. Discontinuation can exacerbate health disparities if individuals from lower socioeconomic backgrounds are less able to sustain treatment due to cost or lack of insurance coverage. Addressing these issues requires a comprehensive approach that considers affordability, patient support programs, and clear guidance on the long-term management strategies for conditions treated with GLP-1 RAs.
The ongoing evolution of GLP-1 receptor agonists, including the development of newer analogs and combination therapies, may influence future discontinuation rates and treatment approachesMost Patients Discontinue GLP-1 Drugs Within a Year .... However, questions persist regarding the sustainability of weight loss and cardiometabolic benefits, as well as the long-term effects of discontinuing these agents作者：D Do·2024·被引用次数：137—One study found a 12-monthdiscontinuationof 45.2% among patients with T2D. In this study, we estimated the prevalence ofGLP-1 agonist.... Future research, particularly longitudinal, real-world studies, will be essential for fully understanding the trajectory of weight regain after cessation and for developing strategies to mitigate the negative consequences of stopping GLP-1 RA therapy. Ultimately, a nuanced understanding of why patients discontinue these powerful medications is key to optimizing their use and ensuring patients can achieve and maintain their health goals2025年9月25日—FDA is aware that some patients and health care professionals may look to unapproved versions ofGLP-1(glucagon-like peptide-1(GLP-1) ....
Join the newsletter to receive news, updates, new products and freebies in your inbox.